Novo Nordisk said the FDA may call for stronger warnings on liraglutide, an experimental diabetes medicine, after two patients who took Byetta -- a similar drug from Amylin Pharmaceuticals and Eli Lilly and Co. -- died because of inflamed pancreases. The agency is working to revise the label for Byetta, which belongs to a class of drugs called incretin mimetics. Novo Nordisk said it found no proof of a "statistically significant" increase in cases of pancreatitis in clinical-trial patients treated with liraglutide.

Full Story:
Bloomberg, Reuters

Related Summaries